| Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity S Hamdy, O Molavi, Z Ma, A Haddadi, A Alshamsan, Z Gobti, S Elhasi, ... Vaccine 26 (39), 5046-5057, 2008 | 298 | 2008 |
| Micelles of poly(ethylene oxide)‐b‐poly(ε‐caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin Z Ma, A Haddadi, O Molavi, A Lavasanifar, R Lai, J Samuel Journal of Biomedical Materials Research Part A: An Official Journal of The …, 2008 | 248 | 2008 |
| Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells M Han, MR Vakili, H Soleymani Abyaneh, O Molavi, R Lai, A Lavasanifar Molecular pharmaceutics 11 (8), 2640-2649, 2014 | 220 | 2014 |
| Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases A Fallah, A Sadeghinia, H Kahroba, A Samadi, HR Heidari, B Bradaran, ... Biomedicine & Pharmacotherapy 110, 775-785, 2019 | 214 | 2019 |
| Enhanced antigen‐specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll‐like receptor ligand monophosphoryl lipid A in poly (D, L‐lactic‐co‐glycolic acid … S Hamdy, P Elamanchili, A Alshamsan, O Molavi, T Satou, J Samuel Journal of biomedical materials research Part A 81 (3), 652-662, 2007 | 160 | 2007 |
| Up-down regulation of HIF-1α in cancer progression M Rashid, LR Zadeh, B Baradaran, O Molavi, Z Ghesmati, M Sabzichi, ... Gene 798, 145796, 2021 | 127 | 2021 |
| Amphiphilic block co-polymers: preparation and application in nanodrug and gene delivery XB Xiong, Z Binkhathlan, O Molavi, A Lavasanifar Acta biomaterialia 8 (6), 2017-2033, 2012 | 125 | 2012 |
| Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors O Molavi, Z Ma, A Mahmud, A Alshamsan, J Samuel, R Lai, GS Kwon, ... International journal of pharmaceutics 347 (1-2), 118-127, 2008 | 123 | 2008 |
| Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment M Sabzichi, N Samadi, J Mohammadian, H Hamishehkar, M Akbarzadeh, ... Colloids and Surfaces B: Biointerfaces 145, 64-71, 2016 | 93 | 2016 |
| Self-Associating Poly(ethylene oxide)-b-poly(α-cholesteryl carboxylate-ε-caprolactone) Block Copolymer for the Solubilization of STAT-3 Inhibitor Cucurbitacin I A Mahmud, S Patel, O Molavi, P Choi, J Samuel, A Lavasanifar Biomacromolecules 10 (3), 471-478, 2009 | 86 | 2009 |
| Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy O Molavi, F Narimani, F Asiaee, S Sharifi, V Tarhriz, A Shayanfar, ... Pharmaceutical biology 55 (1), 729-739, 2017 | 83 | 2017 |
| Resveratrol analog trans 3, 4, 5, 4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol Z Ma, O Molavi, A Haddadi, R Lai, RA Gossage, A Lavasanifar Cancer chemotherapy and pharmacology 63, 27-35, 2008 | 82 | 2008 |
| Preparation and characterization of PLGA-PEG-PLGA polymeric nanoparticles for co-delivery of 5-Fluorouracil and Chrysin S Khaledi, S Jafari, S Hamidi, O Molavi, S Davaran Journal of Biomaterials Science, Polymer Edition 31 (9), 1107-1126, 2020 | 71 | 2020 |
| The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma Y Zhang, O Molavi, M Su, R Lai BMC cancer 14, 1-14, 2014 | 69 | 2014 |
| Development of a Poly(d,l-lactic-co-glycolic acid) Nanoparticle Formulation of STAT3 Inhibitor JSI-124: Implication for Cancer Immunotherapy O Molavi, A Mahmud, S Hamdy, RW Hung, R Lai, J Samuel, ... Molecular pharmaceutics 7 (2), 364-374, 2010 | 62 | 2010 |
| Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer S Jafari, O Molavi, H Kahroba, MS Hejazi, N Maleki-Dizaji, S Barghi, ... Cellular and Molecular Life Sciences 77, 3693-3710, 2020 | 54 | 2020 |
| Hsp70 in cancer: A double agent in the battle between survival and death MA Vostakolaei, L Hatami‐Baroogh, G Babaei, O Molavi, S Kordi, ... Journal of cellular physiology 236 (5), 3420-3444, 2021 | 53 | 2021 |
| Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI‐124 in a mouse melanoma tumor model O Molavi, Z Ma, S Hamdy, R Lai, A Lavasanifar, J Samuel Immunology and Cell Biology 86 (6), 506-514, 2008 | 52 | 2008 |
| Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma O Molavi, XB Xiong, D Douglas, N Kneteman, S Nagata, I Pastan, Q Chu, ... Biomaterials 34 (34), 8718-8725, 2013 | 46 | 2013 |
| STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells S Jafari, A Lavasanifar, MS Hejazi, N Maleki-Dizaji, M Mesgari, O Molavi DARU Journal of Pharmaceutical Sciences 28, 159-169, 2020 | 41 | 2020 |
Afsaneh LavasanifarProfessor, University of AlbertaVerified email at ualberta.ca
